Search

CN-122005651-A - Biological agent based on reduced coenzyme Q10, preparation method and application

CN122005651ACN 122005651 ACN122005651 ACN 122005651ACN-122005651-A

Abstract

The invention discloses a biological agent based on reduced coenzyme Q10, a preparation method and application thereof, belonging to the technical field of biological medicine. The biological agent consists of reduced coenzyme Q10, juniper extract, pine and red plum extract and pharmaceutically acceptable auxiliary materials, and is prepared by a nanoemulsion process. Wherein the mass ratio of the reduced coenzyme Q10 to the juniper extract to the pine and red plum extract is (2-10) to (0.2-1). Experiments on non-alcoholic fatty liver disease rats prove that the biological preparation can effectively regulate dyslipidemia, inhibit inflammation, relieve oxidative stress injury and improve liver mitochondrial dysfunction through multi-target synergistic effect.

Inventors

  • TANG TA
  • TANG ZHENNAN
  • QIU MINGQUAN

Assignees

  • 万物生(深圳)生命科技有限公司

Dates

Publication Date
20260512
Application Date
20260209

Claims (10)

  1. 1. A reduced coenzyme Q10-based biological agent, characterized by comprising reduced coenzyme Q10, juniper extract and pinus koraiensis extract.
  2. 2. The reduced coenzyme Q10-based biological preparation according to claim 1, wherein the mass ratio of reduced coenzyme Q10, juniper extract and pine cone extract is (2-10): (0.2-1).
  3. 3. The reduced coenzyme Q10-based biological preparation according to claim 2, wherein the mass ratio of reduced coenzyme Q10, juniper extract and pine cone extract is (4-10): (0.2-0.8): (0.2-0.6).
  4. 4. The reduced coenzyme Q10-based biological preparation according to any of claims 1-3, further comprising a pharmaceutically acceptable adjuvant.
  5. 5. A method for preparing a reduced coenzyme Q10-based biological agent, comprising the steps of: (1) Preheating lipid matrix at 55-65deg.C, continuously stirring, sequentially adding reduced coenzyme Q10, juniper extract and pine and red plum extract until the system is uniformly mixed to form a uniform oil phase; (2) Mixing the auxiliary agent and part of solvent, and continuously stirring for 12-20min at 55-65 ℃ until the system is uniformly dispersed to form a transparent uniform water phase; (3) Slowly adding the oil phase in the step (1) into the water phase in the step (2) under high-speed shearing to obtain a coarse emulsion; (4) And (3) circularly homogenizing the crude emulsion in the step (3) for 2-3 times under the pressure of 40-60MPa, diluting the crude emulsion with residual solvent to a constant volume to the full prescription amount after homogenizing, and filtering the diluted crude emulsion with a microporous filter membrane with the thickness of 0.45 mu m to obtain the biological preparation.
  6. 6. The method for preparing a reduced coenzyme Q10-based biological agent according to claim 5, wherein the juniper extract in step (1) is prepared by the following method: Pulverizing dried branches and leaves of Juniperus sibirica, sieving with 80 mesh sieve, adding 50% ethanol water solution at a feed-liquid ratio of 1:25, heating and reflux extracting at 55-65deg.C for 1-3 hr, filtering, repeatedly extracting the residue by the same method, mixing the filtrates, concentrating under reduced pressure to 1/10 of the original volume, stirring with 55-65deg.C hot water for dispersion to obtain suspension, degreasing with petroleum ether for 1-3 times, extracting the degreased water phase with n-butanol for 2-4 times, mixing n-butanol phases, concentrating under reduced pressure to relative density of 1.1-1.2, and vacuum drying at 45-55deg.C to obtain Juniperus chinensis extract.
  7. 7. The method for producing a reduced coenzyme Q10-based biological agent according to claim 5, wherein the method for producing the pine-red plum extract in the step (2) is as follows: Pulverizing dried leaves of Pinus koraiensis, sieving with 60 mesh sieve, adding 70% acetone aqueous solution at a feed liquid ratio of 1:20, extracting with ultrasonic assistance, filtering, extracting residue repeatedly under the same condition, mixing filtrates, concentrating under reduced pressure to 1/10 of original volume to obtain water phase concentrate, extracting with ethyl acetate for 2-4 times, mixing all ethyl acetate phases, maintaining temperature unchanged, concentrating under reduced pressure to relative density of 1.1-1.2, and vacuum drying at 40-50deg.C to obtain Pinus koraiensis extract.
  8. 8. The method for preparing a biological preparation based on reduced coenzyme Q10 according to claim 7, wherein the condition of ultrasonic assisted extraction is that the ultrasonic power is 300W, the temperature is 40 ℃ and the time is 30min.
  9. 9. The method for producing a reduced coenzyme Q10-based biological agent according to claim 5, wherein the high-speed shearing parameter in the step (3) is a rotation speed of 10000 to 15000r/min for 3 to 5min.
  10. 10. Use of a biological agent prepared by the preparation method according to any one of claims 5 to 9 for the preparation of a medicament for the treatment and/or prevention of non-alcoholic fatty liver disease.

Description

Biological agent based on reduced coenzyme Q10, preparation method and application Technical Field The invention relates to the technical field of biological medicine, in particular to a biological agent based on reduced coenzyme Q10, a preparation method and application thereof. Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, and its disease spectrum covers simple liver steatosis (non-alcoholic steatosis, NAFL), non-alcoholic steatohepatitis (non-alcoholic steatohepatitis, NASH), and can further progress to cirrhosis and even hepatocellular carcinoma, which has become an important public health problem. The pathogenesis of the disease is complex, and the disease relates to a plurality of core links such as insulin resistance, lipid metabolism disorder, chronic inflammation and the like. Studies have shown that mitochondrial dysfunction and its mediated oxidative stress play an important role in linking the above-described pathological processes, driving NAFLD to occur and progress. In the NAFLD state, excessive accumulation of liver lipids promotes enhanced beta-oxidation of fatty acids, resulting in increased mitochondrial Electron Transport Chain (ETC) electron flow, increased Reactive Oxygen Species (ROS) production, and possibly exceeding the scavenging capacity of endogenous antioxidant systems. Excessive ROS can damage mitochondrial components and mitochondrial DNA, affect ETC function, form malignant circulation of 'ROS accumulation-mitochondrial damage', further activate inflammatory pathways such as NLRP3 inflammatory corpuscles, NF- κB and the like, induce apoptosis, pyrosis and iron death of liver cells, and cause liver inflammation, fibrosis and functional damage. Therefore, targeted intervention in mitochondrial oxidative stress has become a very promising strategy for controlling NAFLD. At present, the intervention strategies aiming at mitochondrial oxidative stress mainly comprise four major categories, but each has certain limitation that (1) a conventional antioxidant (such as vitamin E, N-acetylcysteine and the like) can directly remove ROS, but has the problems of low bioavailability, insufficient mitochondrial targeting, short action duration and the like, and has limited curative effect in long-term application, and (2) a mitochondrial targeting drug such as mitochondrial targeting peptide SS-31, mitochondrial targeting antioxidant MitoQ, coenzyme Q10 (Coenzyme Q, coQ 10) with mitochondrial function and the like can specifically act on mitochondria, and reduce oxidative stress by stabilizing ETC or removing mitochondrial ROS. For example, reduced coenzyme Q10 (panthenol) can be used as an electron carrier and an endogenous antioxidant, liver steatosis can be improved by activating an AMPK pathway and the like, but the single use of the components has relatively single effect in regulating systemic metabolic disorder, inhibiting multiple pathological links such as inflammation, fibrosis and the like, (3) natural active components (such as resveratrol, quercetin, curcumin and the like) generally have multi-target effects, can synergistically play the functions of resisting oxidation, resisting inflammation and regulating metabolism by activating SIRT1/PGC-1 alpha, nrf2/Keap1 and the like, but the components are complicated and different in standardization degree, the mechanism is not completely clear, and (4) signal pathway modulators (such as an AMPK agonist, an Nrf2 activator and the like) can regulate metabolism and resisting oxidation from upstream, but the clinical transformation is still immature at present, and the specificity and safety are required to be further verified. Thus, its application remains a challenge. In conclusion, the existing intervention strategies or targeting are insufficient, or the action is single, or the mechanism is unknown, so that the complex pathological network of NAFLD is difficult to comprehensively cope with. Therefore, developing a synergistic compound preparation with multiple mechanisms of source targeted repair, system metabolism regulation and anti-inflammatory and anti-fibrosis effects becomes an important research direction for breaking through the current treatment bottleneck. Based on the method, the invention is based on reduced coenzyme Q10 and cooperates with juniper extract and pine-red plum extract, and aims to provide a therapeutic scheme with comprehensive mechanism, definite targeting and relatively clear components aiming at NAFLD so as to enrich the drug treatment options of the diseases. Disclosure of Invention Therefore, the invention provides a biological agent based on reduced coenzyme Q10, a preparation method and application thereof, so as to solve the defects in the prior art. In order to achieve the above object, the present invention provides the following technical solutions: According to a first aspect of the present invention, there is provided a reduced